Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGFR1/VEGFR2 Peptide Vaccine + Gemcitabine in Pancreatic Cancer
NCT00655785Phase 2Completed
- Sponsor
- Fukushima Medical University
- Start
- Sep 2007
- Primary completion
- Mar 2013
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of VEGFR1-A24-1084, elpamitide in pancreatic cancer (PC), sponsored by Fukushima Medical University. Started Sep 2007; status: completed.
02
Drugs
VEGFR1-A24-1084elpamitide
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00655785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00655785.